Protein testing to tell apart pancreatic and bile duct cancers
Part of Cancer clinical trials.
This study looks at tissue samples from people who had surgery for pancreatic cancer or a certain type of bile duct cancer. The goal is to find proteins that help tell these two cancers apart, which could lead to better diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had a procedure called a pancreaticoduodenectomy (also known as a Whipple procedure) to treat either pancreatic cancer or a type of bile duct cancer called distal cholangiocarcinoma.
- You cannot have received chemotherapy before your surgery.
- You must agree to allow the use of your medical data for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a way to use blood samples, called liquid biopsies, to find tiny bits of cancer left after surgery and choose the best follow-up treatments for pancreatic cancer. It might help doctors personalize care for each patient.
This study is testing a new lab technique to see if it can accurately diagnose a type of bile duct cancer called cholangiocarcinoma from stored tissue samples. It might help doctors diagnose this cancer more accurately in the future.
This trial tests whether a sample of bile (a fluid produced by your liver) can help doctors diagnose bile duct cancer more accurately. If you have a narrowing in your bile duct and need a procedure to take a tissue sample, you may be able to participate.
This study looks for proteins in the blood that could help doctors tell the difference between pancreatic cancer and non-cancerous pancreatic conditions, such as chronic pancreatitis or benign cysts. By participating, you could help improve early and accurate diagnosis, which may lead to better outcomes for future patients.
This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.